慢性腎臟病(chronic kidney disease)的病人有動脈粥樣硬化和周邊動脈疾病(peripheral
artery disease)增加的風險。在這個研究，我們研究了慢性腎臟病患者和周邊動脈疾病的相關
風險因素，並且以Fukuda Vascular Screening system VaSera VS-1000TM來檢查腳踝和腕上臂血壓比例(ankle-brachial index)，若病人的腳踝和腕上臂血壓比例小於0.9則診斷為周邊動脈疾病。總共包括124名慢性腎臟病第3到5期的患者，慢性腎臟病分期是依據結果質量主動性( K/DOQI)分類，患者都尚未接受透析療法，且先前未被診斷有周邊動脈疾病。總共有22個(17.7%) 參與研究者有周邊動脈疾病。較高的心臟收縮血壓，舒張血壓，及脈壓(pulse
pressure)和周邊動脈疾病之間有較強的相關性。邏輯式回歸分析後，發現在高血壓的慢性腎
臟病患者顯示了風險因素為脈壓，而鈣離子阻斷劑治療在高血壓的慢性腎臟病患者，跟腳踝
和腕上臂血壓比例<0.9有負相關(odds ratio = 0.232, CI = 0.07-0.73, p =0.013)。研究發現周邊動脈疾病在慢性腎臟病患者有較高的盛行率，特別是那些合併有高血壓的患者。腳踝和腕上臂血壓比例 (ABI) 的檢查也許可以常規的使用在慢性腎臟病患者，使慢性腎臟病患者能獲得及早治療周邊動脈疾病的益處。

Patients with chronic kidney disease (CKD) are at increased risk for atherosclerosis and peripheral artery disease (PAD). We studied the possible related risk factors and hypertension treatment in CKD patients with PAD. One hundred and twenty-four patients with stages 3 to 5 of CKD, as described by the Kidney Outcome Quality Initiatives (K/DOQI) classification, were included in this study. Neither the patients
on dialysis nor with PAD were included. The ankle-brachial index (ABI) was calculated using the Fukuda Vascular Screening system VaSera VS-1000TM. Patients were diagnosed with PAD if the ABI for one of the
legs was <0.9. Patient characteristics and their laboratory data were collected. There were 22 (17.7 %)participants with PAD. Higher systolic blood pressure, higher diastolic blood pressure, and increased pulse
pressure showed a strong association with PAD. On further analysis, significantly fewer patients were treated with calcium channel blocker in hypertensive CKD patients with PAD (χ2 =7.055, p=0.008). The
multiple logistic regression analysis in hypertensive patients demonstrated the risk factors for PAD was pulse pressure, and calcium channel blocker treatment negatively correlate with ABI<0.9 in CKD patients (odds ratio=0.232, 95% CI = 0.07-0.73, p=0.013). There was a high prevalent rate of PAD in CKD patients,especially those with hypertension. ABIs may be routinely used for early diagnosis and therapeutic management.（J Intern Med Taiwan 2010; 21: 48-55）